Regarding the percentage of TCD4+ lymphocytes that produce IL-10 and IL-17, the PBMCs from patients with MS stimulated or not with anti-CD3 did not show alterations (Figure 7B,C). This evidence concerns the gene IL17A and myeloid sarcoma.